Use of a New Phototherapy Device (BBloo®) for the Treatment of

Status Recruiting

Clinical Trial Summary

Jaundice occurs in most newborn infants. Most jaundice is benign, but because of the potential toxicity of bilirubin, newborn infants must be monitored to identify those who might develop severe hyperbilirubinemia an, in rare cases, acute bilirubin encephalopathy or kernicterus. Jaundice is a commonly observed, usually harmless condition in newborn infants during the first week after birth. However, in some babies the amount of bilirubin pigment can increase to dangerous levels and require treatment. Treatment of jaundice in newborn infants is done by placing them under phototherapy, a process of exposing their skin to light of a specific wavelength band. Fluorescent tubes or halogen lamps have been used as light sources for phototherapy for many years. A light-emitting diode (LED) is a newer type of light source which is power efficient, has a longer life and is portable with low heat production. Several technologies and devices are developed around this LED and specially a compact system.

The purpose of this study is to evaluate efficacity of LED phototherapy by comparing with conventional phototherapy (non-LED) and satisfaction of the parents and the professional staff about comfort of this new technology. The newborn infant is placed in a sleeper with the device B' bloo ® which maintains him in position (lap or dorsal) allowing to pass the blue light. This one is generated by the module LED and transmitted in the braid of optical fibers which takes place directly on the mattress of the cradle in which is placed the patient usually.

The device is endowed with an hour counter to schedule the time of treatment. The energy illumination varies between 3 and 4 mW / cm ² for an average 3,6 mW / cm ².

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02156050
Study type	Interventional
Source	Association Pédiatrique des Groupes d'Acuueil et de Recherche
Contact	emmanuelle letamendia, MD
Phone	0145374641
Email	emmanuelle.letamendia@abc.aphp.fr
Status	Recruiting
Phase	Phase 4
Start date	December 2013
Completion date	December 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06186349` - The Effect and Mechanism of Gene Variation on Neonatal Hyperbilirubinemia
Recruiting	`NCT04369313` - Effect of DCC on Neonatal Jaundice and Blood Gas Analysis in Infants Born to GDM Mothers	N/A
Not yet recruiting	`NCT04585828` - Comparison of Double Pad Fiber Optic Device Versus Conventional Phototherapy	N/A
Completed	`NCT02927093` - Clinical and Developmental Outcomes of Babies Who Became Yellow in the First Month of Life	N/A
Unknown status	`NCT01340339` - Reverse Phototherapy With Super Light-emitting Diode(Super-LED) for Hyperbilirubinemia in Term and Late Preterm Infants	Phase 4
Completed	`NCT02033096` - Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)
Recruiting	`NCT04218318` - Safe Threshold to Discontinue Phototherapy in Hemolytic Disease of Newborn	N/A
Active, not recruiting	`NCT02602301` - The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels	Phase 4
Completed	`NCT00801619` - Bilicurves: Using Information Technology to Improve the Management of Neonatal Hyperbilirubinemia	N/A
Active, not recruiting	`NCT05343403` - Parental Participation on the Neonatal Ward - the neoPARTNER Study
Completed	`NCT03880591` - Neonatal Hyperbilirubinaemia in the Democratic Republic of Congo
Completed	`NCT01599611` - Follow-up of Extreme Neonatal Hyperbilirubinemia in 5-10 Year Old Children: a Danish Population Based Study	N/A
Recruiting	`NCT06399146` - Evaluation of Bilirubin Estimates in Newborns From Smartphone Digital Images in a Population in Botswana	N/A
Completed	`NCT06018012` - MRA and ABR as Early Predictors of Bilirubin-Induced Neurologic Dysfunction in Full-term Jaundiced Neonates
Completed	`NCT03536078` - Home Phototherapy for Term Newborns With Icterus	N/A
Withdrawn	`NCT00917007` - Measurement of Carboxyhemoglobin by Gas Chromatography as an Index of Hemolysis
Recruiting	`NCT00154960` - Establishing Novel Detection Techniques for Various Genetic-Related Diseases by Applying DHPLC Platform.	N/A
Recruiting	`NCT02594904` - Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency	Phase 4
Completed	`NCT01746511` - Glycerin Suppositories to Reduce Jaundice in Premature Infants	N/A
Completed	`NCT01470820` - Dose-response Relationship of Phototherapy for Hyperbilirubinaemia Using Diodes: is There a "Saturation Point"	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Use of a New Phototherapy Device (BBloo®) for the Treatment of Hyperbilirubinemia in the Newborn Infant — ICT-O2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms